Share on StockTwits

Prothena Co. PLC (NASDAQ:PRTA) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a report released on Tuesday. The firm currently has a $20.00 price target on the stock. Zacks‘s price target would suggest a potential upside of 5.88% from the company’s current price.

Shares of Prothena Co. PLC (NASDAQ:PRTA) traded up 2.17% during mid-day trading on Tuesday, hitting $19.30. The stock had a trading volume of 414,616 shares. Prothena Co. PLC has a 52 week low of $15.00 and a 52 week high of $49.24. The stock has a 50-day moving average of $20.72 and a 200-day moving average of $27.13. The company’s market cap is $422.7 million.

Prothena Co. PLC (NASDAQ:PRTA) last released its earnings data on Monday, August 4th. The company reported $0.06 earnings per share (EPS) for the quarter. The company had revenue of $15.10 million for the quarter.

PRTA has been the subject of a number of other recent research reports. Analysts at Oppenheimer initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, July 10th. They set an “outperform” rating and a $40.00 price target on the stock. Analysts at Ladenburg Thalmann initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, May 22nd. They set a “buy” rating and a $36.50 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $38.79.

Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.